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ventionist cardiology veriﬁed the cost of the management of
bleeding complications. RESULTS: The management cost of 100
patients subjected to PCI and treated with heparin plus abcix-
imab is €89,023.67, and €57,703.76 if treated with bivalirudin,
which results in an incremental cost of €313.2 per patientk. In
the group of patients subjected to PCI, with the bivalirudin
option, and without modifying the hospital budget, 54 out of
100 patients more could be treated with a similar level of pro-
tection and a smaller bleeding risk. CONCLUSIONS: Bivaliru-
dina should be considered as the anticoagulant ﬁrst option in
those patients undergoing PCI and that are currently receving
heparin plus glycoprotein IIb/IIIa inhibition.
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OBJECTIVE: to study direct medical costs for treatment of mild
to moderate hypertension in patients with type II diabetes in the
perspective of the Italian National Health care System (NHS).
METHODS: this was a randomized parallel group clinical study;
after a 2 weeks run-in period, eligible patients DBP≤(90 < 140)
were randomized to treatment with delapril (D) 30≥110; SBP
mg/die, ramipril 2.5 mg/die (R) or valsartan (V) 80 mg/die. After
6 weeks of active treatment, uncontrolled patients were switched
to combination therapies: D + manidipine 10 mg (D + M); R +
hydrochlorothiazide 12.5 mg (R + HCTZ); V + hydrochloroth-
iazide 12.5 mg (V + HCTZ), whilst patients with satisfactory BP
levels were kept on monotherapy. The economic analysis was run
in the perspective of the Italian NHS; only direct medical costs
were considered, including study drugs, unscheduled medical
visits and tests, hypoglycaemic drugs and drugs used to treat
adverse events. Year 2006 market prices and NHS tariffs were
applied; for D + M we considered a target price of €23.24 for
28 tablets pack (not marketed yet in Italy). RESULTS: 425
patients were included (ITT), of which 139 were treated with
D/D + M, 145 with R/R + HCTZ and 141 with V/V + HCTZ.
No statistically signiﬁcant differences were found among the 3
study groups, on the primary efﬁcacy variable of DBP, on the
number of patients requiring combination therapy and on sec-
ondary efﬁcacy parameters. Therefore the economic analysis was
a cost-minimisation analysis with costs normalised at 1 year to
account for slightly different lengths of follow-up. Average costs
per patient/year for D/D + M vs. R/R + HCTZ and V/V + HCTZ
was €643 vs. €636 vs. €759 respectively. CONCLUSION:
the study demonstrates that, despite similar BP control, there are
differences in the NHS annual cost, between patients treated
with ACE inhibitors (with/without diuretic or CCBs) and 
those treated with a speciﬁc angiotensin II receptor antagonist
(with/without diuretic).
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OBJECTIVES: Multiple publications have reported the positive
effects of rehabilitation in cardiac patients, also post-
percutaneous coronary intervention (PCI). However, the cost
remains an important hurdle for the payer to fully support
cardiac rehabilitation. The aim of this study was to, retrospec-
tively, assess the clinical outcomes and associated costs of
patients who underwent PCI with or without rehabilitation in a
Belgian hospital. METHODS: The patient ﬁles of 213 consecu-
tive patients who underwent a PCI between February 1998 and
December 1999 were analysed in January 2006. 133 patients
started a 3-month rehabilitation program, 80 did not. All major
adverse cardiac events (including angina, MI, re-PCI or CABG,
other hospitalisation, cardiovascular and other death) were
reported. All the events that occurred over the study period were
costed using unit cost data from the payer’s perspective obtained
from ofﬁcial sources. The cost of one rehabilitation session is
€23.25. RESULTS: The average follow-up period was 4.8 years.
The average number of rehabilitation sessions performed was
42.1. Less (not signiﬁcantly) patients in the rehabilitation group
were re-hospitalised (43% vs. 56%; p = 0.065) and the number
of re-hospitalisations (more than 1 per patient) for angina (45%
vs. 75%; p < 0.01) and revascularizations (8% vs. 18%; p <
0.05) was signiﬁcantly reduced. Mortality was not different
between the treatment groups. The average cost per patient over
the 4.8 years study period was €4862 (st.err €529) in the reha-
bilitation and €5498 (st.err €741) in the no rehabilitation group
(p = NS). Patients in the rehabilitation group were younger (p <
0.01) but logistic regression analysis (univariate and multivari-
ate) showed no signiﬁcant effect of age on angina and revascu-
larization incidence in the total population. CONCLUSIONS:
The cost of cardiac rehabilitation is more than totally offset by
the signiﬁcant reduction in cardiac events. Based on this study a
cardiac rehabilitation program should be installed in all patients
undergoing PCI.
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OBJECTIVES: The Joint British Societies (JBS) 2005 guideline
on prevention of cardiovascular disease (CVD) advocates pre-
vention in people with established CVD, with diabetes and with
CVD risk ≥20% over 10 years. This study was designed to estab-
lish the number of patients eligible for statin treatment in Scot-
land under these new guidelines, compared to those previously
eligible under the National Service Framework (NSF) for CHD
2000, and estimate the budget impact of treating these additional
patients to the JBS 2 optimal total cholesterol (TC) target of 
<4.0 mmol/L. METHODS: Data from the Scottish Health Survey
2003 (mean baseline TC, incidence of CVD and diabetes) were
combined with predicted coronary heart disease (CHD) risk esti-
mates and population statistics in an Excel-based model to 
estimate number of eligible patients. Efﬁcacy data from the
STELLAR (Statin Therapies for Elevated Lipid Levels compared
Across doses to Rosuvastatin) trial and pack costs from standard
sources were used to determine percentage of patients reaching
the speciﬁed TC target and annual treatment costs for alterna-
tive strategies comprising simvastatin 40 mg followed by either
atorvastatin (20 mg, 40 mg and 80 mg) or rosuvastatin (10 mg,
20 mg and 40 mg). RESULTS: The results using JBS 2, showed
21.3% of the adult population in Scotland is eligible for statin
treatment: a total of 881,402 people. Using the NSF, only 12.4%
or 513,600 people were eligible, this is an increase of 367,802
(8.9%). The cost of treating these additional patients with the
